Asset overview
Program snapshot
Target: mesothelin
Cell type: NK_CELL
Indications: Epithelial Ovarian Cancer
Sponsor: Allife Medical Science and Technology Co., Ltd.
Institution: Allife Medical Science and Technology Co., Ltd.
Car Nk
anti-Mesothelin Car NK Cells
anti-Mesothelin Car NK Cells is flagged as a platform signal because it has an active early-phase oncology cell-therapy trial at Allife Medical Science and Technology Co., Ltd., with a probable patent signal linked through modality_match. Manual review is still required.
Clinical evidence
Trial footprint
Phase: Early Phase1
Status: Unknown
Trial count: 1
Active trials: 0
First posted: October 2, 2018
Last updated: January 31, 2019
Signal summary
IP and BD posture
IP signal: Probable
BD label: Platform Signal
Confidence: Medium
Manual review required: Yes
Scores
Deterministic scoring
Clinical translation1
IP linkage4
Licensing clarity2
Strategic interest3
Source
Public trial record
Review the underlying ClinicalTrials.gov record and treat Treelip output as a prioritization layer, not a final diligence conclusion.
NCT IDs: NCT03692637